delavirdine has been researched along with Acquired Immunodeficiency Syndrome in 11 studies
Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.
Acquired Immunodeficiency Syndrome: An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Delavirdine doses were adjusted weekly until subjects were within their target trough concentration range (3 to 10, 11 to 30, or 31 to 50 microM)." | 2.69 | ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team. ( Demeter, LM; Fischl, M; Freimuth, WW; Holden-Wiltse, J; Meehan, P; Morse, G; Nevin, T; Para, MF; Shafer, R; Virani-Ketter, N; Wood, K, 1999) |
| "Adult AIDS clinical trials units." | 2.69 | Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370. ( Acosta, EP; Bassett, RL; Bell, D; Eron, JJ; Fife, K; Johnson, VA; Kuritzkes, DR; Marschner, IC; Martinez, A; Murphy, RL; Pettinelli, CB; Sommadossi, JP; Wood, K, 2000) |
| "Delavirdine is a nonnucleoside reverse transcriptase inhibitor with in vitro activity against human immunodeficiency virus type 1 (HIV-1) that is currently being evaluated in combination regimens with various nucleoside analogs, including didanosine." | 2.68 | Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. ( Cox, SR; DeRemer, M; Driver, M; Fischl, MA; Freimuth, WW; Morse, GD; Shelton, MJ, 1997) |
| " To provide a rationale for combination therapy with a second-generation bisheteroarylpiperazine, we investigated the effect of U-90152 in combination with 3'-azido-3'-deoxythymidine (AZT) or 2',3'-dideoxycytidine (ddC)." | 1.29 | Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. ( Chong, KT; Hinshaw, RR; Pagano, PJ, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (54.55) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, ZY | 1 |
| Wei, HS | 1 |
| Zhao, HX | 1 |
| Liu, YN | 1 |
| Zhao, Y | 1 |
| Han, N | 1 |
| Cheng, J | 1 |
| Zhang, FJ | 1 |
| Chong, KT | 1 |
| Pagano, PJ | 1 |
| Hinshaw, RR | 1 |
| Morse, GD | 1 |
| Fischl, MA | 1 |
| Shelton, MJ | 1 |
| Cox, SR | 1 |
| Driver, M | 1 |
| DeRemer, M | 1 |
| Freimuth, WW | 2 |
| Esnouf, RM | 1 |
| Ren, J | 1 |
| Hopkins, AL | 1 |
| Ross, CK | 1 |
| Jones, EY | 1 |
| Stammers, DK | 1 |
| Stuart, DI | 1 |
| Para, MF | 1 |
| Meehan, P | 1 |
| Holden-Wiltse, J | 1 |
| Fischl, M | 1 |
| Morse, G | 1 |
| Shafer, R | 1 |
| Demeter, LM | 1 |
| Wood, K | 2 |
| Nevin, T | 1 |
| Virani-Ketter, N | 1 |
| Eng, KT | 1 |
| Liu, ES | 1 |
| Silverman, MS | 1 |
| Berger, AR | 1 |
| Kuritzkes, DR | 1 |
| Bassett, RL | 1 |
| Johnson, VA | 1 |
| Marschner, IC | 1 |
| Eron, JJ | 1 |
| Sommadossi, JP | 1 |
| Acosta, EP | 1 |
| Murphy, RL | 1 |
| Fife, K | 1 |
| Bell, D | 1 |
| Martinez, A | 1 |
| Pettinelli, CB | 1 |
| Campiani, G | 1 |
| Ramunno, A | 1 |
| Maga, G | 1 |
| Nacci, V | 1 |
| Fattorusso, C | 1 |
| Catalanotti, B | 1 |
| Morelli, E | 1 |
| Novellino, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)[NCT00000810] | Phase 1 | 120 participants | Interventional | Completed | |||
| Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects[NCT00000882] | Phase 2 | 300 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for delavirdine and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzodiazepinones; Benzoxazines; Cyclo | 2002 |
3 trials available for delavirdine and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Cross-Over Studies; Delavirdine; Didanos | 1997 |
ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Delavirdine; Dose- | 1999 |
Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; C | 2000 |
7 other studies available for delavirdine and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
Pharmacia pilots patent share for HIV drug.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Delavirdine; Drug Industry; Humans; Patents as | 2003 |
[HIV-1 genotypic resistance profiles in children failing highly active antiretroviral therapy].
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Hi | 2007 |
Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Delavirdine; Drug Synergism; HIV Reverse Trans | 1994 |
[A new AIDS drug in evaluation].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Delavirdine; Didanosine; Dose-Response Relatio | 1993 |
Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Delavirdine; Drug Resistance, Microbial; HIV Re | 1997 |
Lipemia retinalis in acquired immunodeficiency syndrome treated with protease inhibitors.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cholesterol; Delavirdine; Drug Therapy, Combination; HIV | 2000 |
FDA Advisory Committee stalemates on delavirdine.
Topics: Acquired Immunodeficiency Syndrome; CD4 Lymphocyte Count; Clinical Trials as Topic; Delavirdine; Dis | 1997 |